| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 30 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
Subjects between 50 and 80 that suffered from non-clinical cognitive impairment has improvement as measured by the 'Revised Hasegawa Dementia Scale' with 3g of 96% Yamabushitake daily for 16 weeks.
